---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268649016.md"
description: "Merck Animal Health has received conditional approval from the FDA for EXZOLT CATTLE-CA1, a drug used for the prevention and treatment of New World screw-worm larval infections in cattle, which will be available by prescription in the first quarter of 2026"
datetime: "2025-12-04T17:16:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268649016.md)
  - [en](https://longbridge.com/en/news/268649016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268649016.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/268649016.md) | [繁體中文](https://longbridge.com/zh-HK/news/268649016.md)


# 

Merck Animal Health has received conditional approval from the U.S. Food and Drug Administration (FDA) for EXZOLT CATTLE-CA1. This is a pour-on solution used for the prevention and treatment of infections caused by New World screwworm larvae in cattle. The drug will be available by prescription in the first quarter of 2026

### Related Stocks

- [Merck & Co., Inc. (MRK.US)](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Infinimmune, Merck enter into antibody discovery pact](https://longbridge.com/en/news/281193725.md)
- [Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential](https://longbridge.com/en/news/280868524.md)
- [Rare disease advocacy group urges Trump administration to restore FDA clarity](https://longbridge.com/en/news/281367443.md)
- [Fda issuance of a priority review voucher to the sponsor of a rare pediatric disease product application- federal register website](https://longbridge.com/en/news/281378968.md)
- [10:19 ETVascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis](https://longbridge.com/en/news/281386093.md)